New Warfarin PGx Study Will Test New Dosing Algorithms, Aim to Avoid Criticisms of Past Trials | GenomeWeb

Originally published April 12.

By Turna Ray

Brian Gage, an expert on pharmcogenomically-guided warfarin dosing, is leading a new study looking at how genetic testing can personalize the administration of the highly variable anticoagulant in orthopedic patients. This study will apply new PGx dosing algorithms in this patient subset and will hopefully avoid some of the design pitfalls of past clinical trials in this area.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.